Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,580.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,599.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1454.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,578.0,1.0,=,2.5
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1582.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1904.0,1.0,=,0.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2180.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1845.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2340.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2100.0,1.0,=,1.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2881.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,4304.0,1.0,=,0.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3943.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,4304.0,1.0,=,0.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,608.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,376.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,625.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,390.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,893.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1001.0,1.0,=,0.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,912.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,542.0,1.0,=,1.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1177.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,409.0,1.0,=,2.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1190.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1056.0,1.0,=,1.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1309.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,927.0,1.0,=,1.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1357.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,752.0,1.0,=,1.8